CN101454341B - 表面核仁素的多价合成配体在治疗癌症或发炎中的用途 - Google Patents

表面核仁素的多价合成配体在治疗癌症或发炎中的用途 Download PDF

Info

Publication number
CN101454341B
CN101454341B CN2007800192705A CN200780019270A CN101454341B CN 101454341 B CN101454341 B CN 101454341B CN 2007800192705 A CN2007800192705 A CN 2007800192705A CN 200780019270 A CN200780019270 A CN 200780019270A CN 101454341 B CN101454341 B CN 101454341B
Authority
CN
China
Prior art keywords
cell
compound
paranuclein
nucant
carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800192705A
Other languages
English (en)
Chinese (zh)
Other versions
CN101454341A (zh
Inventor
J·库尔蒂
A·荷瓦耐森
J·P·白里安
G·吉夏尔
Y·哈马
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Publication of CN101454341A publication Critical patent/CN101454341A/zh
Application granted granted Critical
Publication of CN101454341B publication Critical patent/CN101454341B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2007800192705A 2006-04-27 2007-04-22 表面核仁素的多价合成配体在治疗癌症或发炎中的用途 Expired - Fee Related CN101454341B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0603813A FR2900341B1 (fr) 2006-04-27 2006-04-27 Utilisation de ligands synthetiques multivalents de la nucleoline de surface pour le traitement du cancer
FR0603813 2006-04-27
PCT/FR2007/000730 WO2007125210A2 (fr) 2006-04-27 2007-04-27 Utilisation de ligands synthetiques multivalents de la nucleoline de surface pour le traitement du cancer ou de l'inflammation

Publications (2)

Publication Number Publication Date
CN101454341A CN101454341A (zh) 2009-06-10
CN101454341B true CN101454341B (zh) 2013-11-06

Family

ID=37597789

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800192705A Expired - Fee Related CN101454341B (zh) 2006-04-27 2007-04-22 表面核仁素的多价合成配体在治疗癌症或发炎中的用途

Country Status (8)

Country Link
US (3) US8497349B2 (https=)
EP (2) EP2540737B1 (https=)
JP (1) JP5559531B2 (https=)
CN (1) CN101454341B (https=)
AU (1) AU2007245551B2 (https=)
CA (1) CA2650485C (https=)
FR (1) FR2900341B1 (https=)
WO (1) WO2007125210A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2900341B1 (fr) 2006-04-27 2012-09-14 Centre Nat Rech Scient Utilisation de ligands synthetiques multivalents de la nucleoline de surface pour le traitement du cancer
EP2291390B1 (en) * 2008-05-22 2014-11-05 Centre National de la Recherche Scientifique (CNRS) New optically pure compounds for improved therapeutic efficiency
FR2947455B1 (fr) 2009-07-01 2014-01-03 Centre Nat Rech Scient La dermaseptine b2 comme inhibiteur de la croissance tumorale
CN103402531A (zh) * 2010-10-04 2013-11-20 国家科学研究中心 作为抗生素治疗的多价合成化合物
WO2013192628A1 (en) * 2012-06-22 2013-12-27 University Of South Florida Peptoid-peptide hybrids and their use
US10213482B2 (en) 2014-12-12 2019-02-26 Immupharma France Sa Methods of treating chronic inflammatory diseases
DK3430031T3 (da) * 2016-03-15 2022-01-17 Idp Discovery Pharma S L Peptider med anti-kræftaktivitet
CA3067674A1 (en) * 2017-06-29 2019-01-03 Ureka Sarl Pro-drug peptide with improved pharmaceutical properties
WO2022223544A1 (en) 2021-04-19 2022-10-27 Centre National De La Recherche Scientifique (Cnrs) COMBINATION THERAPY OF NUCANT AND mTOR INHIBITORS FOR TREATING CANCER

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995029190A1 (fr) * 1994-04-22 1995-11-02 Institut Pasteur Multirepresentation d'un analogue peptidique du substrat de la dppiv, notamment de type kpr, afin d'inhiber l'entree du hiv dans les cellules

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) * 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) * 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) * 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) * 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) * 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) * 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
FR2437213A1 (fr) * 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
US4366241A (en) * 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4957939A (en) * 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4472509A (en) * 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US5891737A (en) 1995-06-07 1999-04-06 Zymogenetics, Inc. Combinatorial non-peptide libraries
US6121236A (en) * 1998-03-24 2000-09-19 The Children's Medical Center Corporation Multivalent ligands which modulate angiogenesis
EP1181304B1 (en) 1999-04-08 2007-10-10 Antisoma Research Limited Antiproliferative activity of g-righ oligonucleotides and method of using same to bind to nucleolin
US6783952B1 (en) 1999-09-16 2004-08-31 Warner-Lambert Company Secreted soluble α2δ-2, α2δ-3 or α2δ-4 calcium channel subunit polypeptides and screening assays using same
FR2809960B1 (fr) 2000-06-07 2004-04-23 Pasteur Institut Composition adjuvante de la reponse immunitaire comprenant la proteine fha ou un fragment de la proteine fha sous forme libre, et composition immunogene ou vaccinale contenant une telle composition adjuvante
FR2828207B1 (fr) 2001-08-02 2004-12-24 Centre Nat Rech Scient Milieux de reaction pour l'activite thymidylate synthase de la thyx
US20040002457A1 (en) * 2002-03-12 2004-01-01 Hovanessian Ara V. Inhibition of virus anchorage by RGG domain of a cell surface-expressed protein, polynucleotide coding for said RGG domain, therapeutic uses thereof by inhibition of microorganism or protein ligand binding to the cell-surface-expressed protein
US7544767B2 (en) * 2002-04-05 2009-06-09 Burnham Institute For Medical Research HMGN2 peptides and related molecules that selectively home to tumor blood vessels and tumor cells
US7357928B2 (en) * 2002-04-08 2008-04-15 University Of Louisville Research Foundation, Inc. Method for the diagnosis and prognosis of malignant diseases
FR2840307B1 (fr) * 2002-05-30 2006-07-07 Centre Nat Rech Scient Nouvelles molecules multimeriques, leur procede de preparation, et leur utilisation pour la preparation de medicaments
TW200504210A (en) * 2003-07-30 2005-02-01 Chin-Tarng Lin A nucleolin antisense inhibiting growth of cancer cell
US20080234464A1 (en) * 2005-04-22 2008-09-25 Hisafumi Ikeda Compound Having Amino Acid Residue or Peptide Residue and Process for Producing the Same
FR2900341B1 (fr) 2006-04-27 2012-09-14 Centre Nat Rech Scient Utilisation de ligands synthetiques multivalents de la nucleoline de surface pour le traitement du cancer
DE602007010459D1 (de) 2007-09-04 2010-12-23 Inst Nat Sante Rech Med Verwendung von Verbindungen, die die EF-Tu-Nucleolin Wechselwirkung vehindern, zur Verhinderung oder Behandlung von Tularämie
EP2291390B1 (en) 2008-05-22 2014-11-05 Centre National de la Recherche Scientifique (CNRS) New optically pure compounds for improved therapeutic efficiency
CN103402531A (zh) 2010-10-04 2013-11-20 国家科学研究中心 作为抗生素治疗的多价合成化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995029190A1 (fr) * 1994-04-22 1995-11-02 Institut Pasteur Multirepresentation d'un analogue peptidique du substrat de la dppiv, notamment de type kpr, afin d'inhiber l'entree du hiv dans les cellules

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
B. Krust et al..The anti-HIV pentameric pseudopeptide HB-19 is preferentially taken up in vivo by lymphoid organs where it forms a complex with nucleolin.《PNAS》.2001,第98卷(第24期),14090-14095. *
Se´bastien Nisole et al..The Anti-HIV Pentameric Pseudopeptide HB-19 Binds the C-terminal End of Nucleolin and Prevents Anchorage of Virus Particles in the Plasma Membrane of Target Cells.《THE JOURNAL OF BIOLOGICAL CHEMISTRY》.2002,第277卷(第23期),20877-20886. *

Also Published As

Publication number Publication date
CA2650485C (en) 2018-12-11
US20160200783A1 (en) 2016-07-14
WO2007125210A8 (fr) 2009-10-22
FR2900341A1 (fr) 2007-11-02
EP2540737A1 (fr) 2013-01-02
AU2007245551A2 (en) 2009-11-19
EP2013232B1 (fr) 2015-05-20
JP2009534451A (ja) 2009-09-24
AU2007245551B2 (en) 2012-03-29
EP2013232A2 (fr) 2009-01-14
US20110065649A1 (en) 2011-03-17
US9254309B2 (en) 2016-02-09
EP2540737B1 (fr) 2015-07-01
WO2007125210A2 (fr) 2007-11-08
WO2007125210A3 (fr) 2008-10-30
CN101454341A (zh) 2009-06-10
US20140073555A1 (en) 2014-03-13
CA2650485A1 (en) 2007-11-08
FR2900341B1 (fr) 2012-09-14
US8497349B2 (en) 2013-07-30
JP5559531B2 (ja) 2014-07-23
AU2007245551A1 (en) 2007-11-08

Similar Documents

Publication Publication Date Title
CN101454341B (zh) 表面核仁素的多价合成配体在治疗癌症或发炎中的用途
JP6514259B2 (ja) 抗炎症活性を有するペプチド、及びそれを含む組成物
JP6546232B2 (ja) 抗炎症活性を有するペプチド、及びそれを含む組成物
TWI743528B (zh) 與IL-2Rβ結合的化合物
ES2361621T7 (es) Peptidos de lactoferrina utiles como peptidos de penetracion celular.
KR101572286B1 (ko) 조직 손상 관련 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체
DK2707014T3 (en) Dimeric high affinity inhibitors of PSD-95 and their use in the treatment of ischemic brain injury and pain
KR20080106432A (ko) ＩｇＧ와 ＦｃＲｎ의 결합을 차단하는 펩티드
CA2732108A1 (en) Prominin-1 peptide fragments and uses thereof
KR101051785B1 (ko) 암세포를 선택적으로 사멸시키기 위한 ＲａｓＧＡＰ 유래펩티드
US20150359842A1 (en) Pro-angiogenic fragments of prominin-1 and uses thereof
ES2359396T3 (es) Anticuerpos bag3 para su uso en investigación , diagnóstico y tratamiento de enfermedades relacionadas con la muerte celular.
US20110124552A1 (en) GMCSF and Truncated CCL2 Conjugates and Methods and Uses Thereof
ES2971898T3 (es) Nuevos compuestos peptídicos obtenidos a partir de IL-4-/IL-13 para el tratamiento o la prevención de enfermeda-des neurodegenerativas o neuroinflamatorias
JP2009521917A (ja) Ｃｘｃｒ４および／または細胞運動の阻害
EP2032601B1 (en) Peptides regulating the surface expression of the t cell receptor
AU2022203041A1 (en) Il-2 receptor binding compounds
Sundaram Expression And Function Of Human IkappaBzeta In Lung Inflammation
WO2005056581A2 (en) Peptide able to specifically bind a chemokine receptor and use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CI01 Publication of corrected invention patent application

Correction item: Date of application and international date of application

Correct: 2007.4.27

False: 2007.4.22

Number: 23

Page: 1116

Volume: 25

CI02 Correction of invention patent application

Correction item: Date of application and international date of application

Correct: 2007.4.27

False: 2007.4.22

Number: 23

Page: The title page

Volume: 25

ERR Gazette correction

Free format text: CORRECT: APPLICATION DATE AND - INTERNATIONAL APPLICATION DATE; FROM: 2007.4.22 TO: 2007.4.27

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20131106